2025年10月1日, Trump将对进口品牌药品征收100%的关税, 除非美国以国家安全为由开始生产。 On October 1, 2025, Trump will impose 100% tariffs on imported branded drugs unless production begins in the U.S., citing national security.

2025年10月1日, 特朗普总统将对进口品牌和专利药品征收100%的关税, 除非制造商已开始在美国设施上建造, On October 1, 2025, President Trump will impose a 100% tariff on imported branded and patented pharmaceuticals unless manufacturers have begun construction on U.S. facilities, defined as breaking ground or being under construction. 这一行动以第232节下国家安全调查为依据,目的是在对供应链脆弱性的关切中提高国内生产。 The move, based on a national security probe under Section 232, aims to boost domestic production amid concerns over supply chain vulnerabilities. 根据事先协议,豁免可能适用于一些欧盟和日本公司,但细节仍不清楚。 Exemptions may apply to some EU and Japanese firms under a prior agreement, but details remain unclear. 行政当局还对医疗设备和用品启动了新的第232条调查。 The administration also launched a new Section 232 investigation into medical equipment and supplies. 在资格、执行和对药物价格和供应的潜在影响方面仍然存在不确定性,行业领导人敦促明确并警告可能发生的中断。 Uncertainty persists over eligibility, enforcement, and potential impacts on drug prices and availability, with industry leaders urging clarity and warning of possible disruptions.